United States Patent 11,040,042: Scope, Claim Construction, and Landscape for an IV Pharmaceutical Composition
What does U.S. Patent 11,040,042 claim?
U.S. Patent 11,040,042 is directed to a pharmaceutical composition for intravenous (IV) administration that contains:
- A pharmaceutically acceptable carrier
- An effective amount of a specific compound defined by a structural formula (the operative “compound of the structure”)
- Optionally, a pharmaceutically acceptable salt of that compound
- With claim 2 narrowing to a hydrochloride salt form
Core claim elements (from the provided claim text)
| Claim |
Scope anchor |
Limitation detail |
Administration route constraint |
| 1 |
Compound of the structure (and its pharmaceutically acceptable salts) |
Composition includes a pharmaceutically acceptable carrier and an “effective amount” |
Suitable for intravenous administration |
| 2 |
Claim 1 compound |
Compound is specifically hydrochloride salt |
Inherits IV suitability from claim 1 |
Practical construction of “suitable for intravenous administration”
From a patent-enforcement perspective, claim 1 does not require a particular formulation recipe (e.g., exact excipients, pH, tonicity, concentration). Instead, it requires that the composition is formulable for IV use. That typically invites arguments on whether accused products are prepared and presented in an IV-ready form (e.g., sterile, buffered/pH-adjusted, isotonic or otherwise IV-compliant). The claim text you provided does not add these formulation parameters, so the enforceable boundary is generally the presence of an IV-compatible composition containing the claimed compound (or salts).
What is the scope of claim 1 versus claim 2?
Claim 1: composition claim with broad compound coverage (structure + salts)
Claim 1 covers:
- Any pharmaceutical composition meeting:
- composition type: “pharmaceutical composition”
- components: “pharmaceutically acceptable carrier” + “effective amount”
- API: compound matching the provided structure or a pharmaceutically acceptable salt of that compound
- route: suitable for intravenous administration
Scope impact: Claim 1 can extend across multiple salt forms (not just hydrochloride), as long as the salt qualifies as “pharmaceutically acceptable.”
Claim 2: salt-form narrowing to hydrochloride
Claim 2 covers:
- The claim 1 composition
- Where the compound is in the hydrochloride salt form
Scope impact: Even if claim 1 covers multiple salts, claim 2 specifically targets hydrochloride.
How might the claim language map to enforceable product categories?
Below are product categories that are likely to fall within the claim language, based strictly on the elements present in claims 1 and 2:
Category A: IV formulations using the named compound (or any pharmaceutically acceptable salt)
- A sterile IV injectable formulation containing the compound of the structure
- The compound may be present as:
- the free base/form if applicable, or
- any pharmaceutically acceptable salt (including non-hydrochloride salts), provided the final composition is IV-suitable
Category B: IV formulations using the hydrochloride salt specifically
- The same IV formulation concept, but the API is constrained to the hydrochloride salt
Category C: Non-IV products
- If the formulation is not “suitable for intravenous administration,” it falls outside claim 1’s route limitation as written.
- The claim text you provided does not define “suitable,” so enforcement will turn on formulation intent and usability for IV delivery.
What does the claims set imply about the underlying patent thesis?
The claim set is composition-centric and route-restricted. It does not, on its face, claim:
- manufacturing steps
- methods of treatment
- dosing regimens
- specific excipient systems or physicochemical targets
That means the value proposition of the patent is concentrated in:
- the IV-ready composition embodiment(s), and
- the salt-form scope (general salts in claim 1; hydrochloride in claim 2)
What is the patent landscape risk for competitors?
Given only the two claims you provided, the most actionable landscape analysis is claim-adjacent freedom-to-operate risk by substitution type. Because claim 1 is limited by:
1) use of the compound defined by the structure, and
2) IV suitability, and
3) carrier + effective amount formulation,
risk is driven by whether a competitor can:
- avoid the exact compound (structure) entirely, or
- avoid IV-suitability, or
- use a non-salt form that still is not within “pharmaceutically acceptable salt” coverage, or
- change salt form away from hydrochloride to avoid claim 2
Competitive design-around levers (based on claim wording)
| Design lever |
How it could reduce risk |
Which claim it mainly affects |
| Use a different active compound not matching the claimed structure |
Removes infringement basis |
Both claims 1 and 2 |
| Use a pharmaceutically acceptable salt different from hydrochloride |
Keeps claim 1 exposure but may avoid claim 2 |
Claim 2 |
| Deliver by non-IV route (oral, subcutaneous, intramuscular) |
Breaks the route limitation (“suitable for intravenous administration”) |
Claim 1 |
| Present a formulation that is not IV-suitable (e.g., not an injectable/IV-ready form) |
Breaks the route limitation |
Claim 1 |
What parts of the claim likely generate the biggest prosecution and litigation focus?
Even without the full specification text, the claim elements indicate usual dispute points:
1) Whether the API matches the “compound of the structure”
- The core infringement question is structural identity.
2) Whether the candidate API form is within “pharmaceutically acceptable salt”
- For claim 1, multiple salt forms are in-bounds if they are pharmaceutically acceptable.
3) Whether the final product is “suitable for intravenous administration”
- This drives formulation-specific evidence (sterility, pH, compatibility, excipient selection, and the manufacturer’s intended administration route).
How to read claim 1 for licensing and diligence
For commercial and investment diligence, claim 1 should be treated as a composition-of-the-drug-for-IV protection layer:
- If your product is IV and includes the claimed compound (or its pharmaceutically acceptable salts), the claim is directly implicated.
- If your product is non-IV, it likely falls outside the literal scope based on the route language.
How to read claim 2 for salt-form targeting
Claim 2 is a hydrochloride-specific IV composition claim.
- If your IV product uses the hydrochloride salt of the claimed compound, claim 2 is directly implicated.
- If your IV product uses a different salt, claim 2 may not apply, but claim 1 still likely applies if the salt is “pharmaceutically acceptable” and the compound identity matches.
Where are the main gaps in your provided claim set?
The claims you provided are short and do not include:
- explicit formulation parameters (pH, osmolality, tonicity, concentration ranges)
- specific carriers/excipients
- defined manufacturing steps
- method-of-treatment claims
This matters for landscape mapping because it can broaden claim coverage to any IV-suitable formulation, but it also means that non-infringement defenses can focus on factual suitability for IV and compound identity.
Patent landscape overview (what can and cannot be derived from the claim text alone)
From the information supplied, a comprehensive landscape chart (e.g., related-family members, co-pending continuation claims, expiration dates, assignees, and citation networks) cannot be produced. The patent landscape is highly dependent on bibliographic data and claim numbers beyond the two you provided (including dependent claims, claim charts, and citation lists). Without those data, any attempt to list competitors, expiry, or cited patents would risk being inaccurate.
Accordingly, the only defensible landscape statements here are those driven directly by the claim elements you supplied: the patent targets IV-suitable formulations of a specific structural compound and its hydrochloride salt.
Key Takeaways
- Claim 1 covers IV-suitable pharmaceutical compositions containing the specific compound of the structure (or any pharmaceutically acceptable salt) plus a pharmaceutically acceptable carrier.
- Claim 2 narrows to the hydrochloride salt form while inheriting the IV-suitable composition requirement.
- The dominant infringement and design-around questions are:
- whether your API matches the claimed structure
- whether your salt form is within “pharmaceutically acceptable salts”
- whether your formulation is actually suitable for intravenous administration
- A competitor can reduce claim 2 exposure by using a non-hydrochloride salt, but that does not eliminate claim 1 exposure if the composition is still IV-suitable and uses a salt within claim 1’s definition.
FAQs
1) Does claim 1 require the compound to be a hydrochloride salt?
No. Claim 1 covers the compound of the structure and pharmaceutically acceptable salts generally. Hydrochloride is only specified in claim 2.
2) Can a competitor avoid infringement by using a different carrier?
The claims require a “pharmaceutically acceptable carrier,” but they do not restrict which carrier. Changing carriers alone is unlikely to avoid infringement if the formulation remains IV-suitable and includes the claimed compound.
3) What is the most direct design-around to claim 1?
Using an API that does not match the compound of the structure, or using a formulation that is not suitable for intravenous administration.
4) If an IV product uses a non-hydrochloride salt, is claim 2 avoided?
Yes, claim 2 is hydrochloride-specific. Claim 1 may still apply if the salt is pharmaceutically acceptable.
5) Do the provided claims include dosing or treatment steps?
No. The claims provided are limited to a pharmaceutical composition and do not include dosing regimens or methods of treatment.
References
[1] Provided claim text for U.S. Patent 11,040,042 (Claims 1-2).
